TrueMed key facts
as of Oct 2026- Developer of a healthcare platform designed to enable consumers to use pre-tax HSA/FSA funds for proactive health and wellness purchases.
- TrueMed is valued at approximately $158.5M as of Oct 2026, set at its early-stage round, Mar 2025; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $44.0M across 1 recorded rounds; the latest was Early Stage VC (Series A) ($34.0M) in Mar 2025.
- Notable investors include Bessemer Venture Partners, M2O, Granite Point Partners, Highland Creek Partners, Learn Capital — 9 tracked in total.
- Status: Privately Held (backing).
Valued at $158.5M at its early-stage round, Mar 2025. Nothing has traded since.
- ·Watch TrueMed: the Monday email on marks, rounds and moves
TrueMed funding rounds
1 roundsTrueMed valuation
TrueMed was valued at $159 million at its early-stage round in Mar 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has TrueMed raised?
TrueMed has raised $44 million in total; 1 of its rounds is on record. The largest on record was a $34 million Series A in Mar 2025.
TrueMed investors
9 investors are on record for TrueMed, including Bessemer Venture Partners, M2O, Granite Point Partners and Highland Creek Partners. The Series A in Mar 2025 drew 6 investors.
Comparable companies
About TrueMed
Developer of a healthcare platform designed to enable consumers to use pre-tax HSA/FSA funds for proactive health and wellness purchases. The company's platform offers a qualification process for obtaining a letter of medical necessity for purchasing fitness equipment and supplements, enabling health-conscious individuals to enhance their health and well-being efficiently.
- Industry
- Specialty Retail
- Sector
- Consumer Products and Services (B2C)
- HQ
- Austin, TX, United States
- Founded
- 2022
- Employees
- 3
- Website
- truemed.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.